AstraZeneca: Farxiga wins fast-track FDA designation
(CercleFinance.com) - AstraZeneca said on Tuesday that it has won "fast track" designation from the US Food and Drug Administration for its Farxiga drug in chronic kidney disease.
The FDA's designation was granted for the development of Farxiga to delay the progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease, the drugmaker said.
The "fast track" programme is designed to accelerate the review of new treatments for serious conditions, where there is an unanswered need for treatment.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The FDA's designation was granted for the development of Farxiga to delay the progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease, the drugmaker said.
The "fast track" programme is designed to accelerate the review of new treatments for serious conditions, where there is an unanswered need for treatment.
Copyright (c) 2019 CercleFinance.com. All rights reserved.